A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Clinical trial NCT04856917 · COMPLETED
Trial details
- NCT number
- NCT04856917
- Sponsor
- Vanda Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-15
- Primary completion
- 2022-02-01
- Enrollment
- 123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.